Jardiance Medicaid Coverage by State Tier

Why Medicaid Tier Placement Matters for Jardiance

Medicaid formularies are not uniform across states. Each state Medicaid program operates its own preferred drug list (PDL), and where Jardiance lands on that list determines what a patient pays and what paperwork their prescriber must complete.

Preferred vs. Non-Preferred Status

A drug listed as "preferred" on a state PDL typically requires no prior authorization and carries the lowest available cost-sharing. "Non-preferred" brand drugs often require prior authorization (PA), step therapy through a cheaper alternative, or both. For Jardiance, a brand-only SGLT2 inhibitor with no current generic, most state Medicaid programs place it as non-preferred because metformin, sulfonylureas, and sometimes other SGLT2 agents (dapagliflozin, canagliflozin) are available at lower cost to the state.

The Centers for Medicare and Medicaid Services (CMS) requires each state to cover outpatient drugs under Medicaid if the manufacturer has signed a rebate agreement, which Boehringer Ingelheim has done. Coverage is therefore guaranteed; the tier and PA burden are what varies. CMS Medicaid drug rebate program overview is publicly searchable, and individual state PDL documents are posted on each state Medicaid agency website.

Prior Authorization Criteria

When a state requires PA for Jardiance, the typical criteria include: documented type 2 diabetes diagnosis, HbA1c above a threshold (commonly 7.5 to 8.0%), trial and failure or contraindication to metformin, and sometimes trial and failure of a preferred SGLT2 agent or GLP-1 receptor agonist. For the heart failure indication (HFrEF, LVEF <40%), PA criteria generally require a cardiology or internal medicine prescriber and documented echocardiographic evidence. The FDA-approved label for empagliflozin summarizes these indications in detail (FDA label, NDA 204629).

State-by-State Tier Overview

No single federal database publishes all 50 state Medicaid PDL tiers in real time, but CMS's Medicaid.gov drug page and state agency websites are updated quarterly. The table below reflects published PDL information available as of January 2026. Verify with each state's Medicaid agency before prescribing or counseling a patient, because formularies change mid-year.

States Where Jardiance Is Preferred (Lower PA Burden)

A smaller group of states has placed at least one SGLT2 inhibitor as preferred for the heart failure or CKD indication rather than diabetes alone. California's Medi-Cal, for example, has listed empagliflozin as preferred for HFrEF following the 2021 FDA label expansion, citing the EMPEROR-Reduced trial (N=3,730), in which empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25% versus placebo (Packer M et al., NEJM 2020). New York Medicaid and Massachusetts MassHealth similarly moved empagliflozin to preferred status for the CKD indication after the EMPA-KIDNEY trial data were published.

States With Non-Preferred Placement and Step Therapy

The majority of state Medicaid programs, including Texas, Florida, Ohio, Georgia, and Pennsylvania, list Jardiance as non-preferred and require step therapy through at least one preferred agent. In practice, this means a prescriber must document that the patient tried and failed (or cannot tolerate) a preferred drug before Jardiance will be approved. Metformin is the near-universal first step. Several of these states also require a second step through a preferred SGLT2 agent such as dapagliflozin 10 mg, which has a similar Medicaid rebate structure.

Medicaid Managed Care vs. Fee-for-Service Nuances

Approximately 70% of Medicaid enrollees are in managed care organizations (MCOs) rather than fee-for-service (FFS) Medicaid. MCOs have flexibility to maintain their own formularies, which may differ from the state FFS PDL. A patient enrolled in a Texas Medicaid MCO plan may face different PA criteria than a patient on FFS Texas Medicaid, even in the same zip code. Prescribers should verify coverage with the specific MCO plan ID listed on the patient's Medicaid card.

Clinical Rationale for Preferring Empagliflozin in High-Risk Patients

Understanding why a provider might push through a PA for Jardiance rather than accepting a formulary alternative requires knowing the outcome data.

EMPA-REG OUTCOME: The Cardiovascular Landmark

EMPA-REG OUTCOME (N=7,020) enrolled adults with type 2 diabetes and established cardiovascular disease. Empagliflozin 10 mg or 25 mg daily reduced the primary three-point MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) by 14% versus placebo (HR 0.86, 95% CI 0.74 to 0.99). The cardiovascular mortality reduction was 38% (HR 0.62, 95% CI 0.49 to 0.77). This was the first glucose-lowering drug to show a statistically significant reduction in cardiovascular mortality in a dedicated outcomes trial (Zinman B et al., NEJM 2015).

EMPA-KIDNEY: Renal Protection Data

EMPA-KIDNEY (N=6,609) enrolled adults with CKD (eGFR 20 to 45 mL/min/1.73 m² or eGFR 45 to 90 with urinary albumin-to-creatinine ratio >200 mg/g). Empagliflozin 10 mg daily reduced the primary composite of kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) (Herrington WG et al., NEJM 2023). This trial supported the FDA's 2023 label expansion for CKD and has been central to state Medicaid PA appeal arguments.

ADA Guidelines and the Preferred Agent Question

The American Diabetes Association Standards of Care in Diabetes (2025 edition) recommends that patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD receive an SGLT2 inhibitor with proven cardiovascular or renal benefit, independent of baseline HbA1c (ADA Standards of Care 2025). This guideline language is directly citable in PA appeals when a state's step-therapy requirement would otherwise mandate a sulfonylurea or other agent without outcomes data.

How to Get Jardiance Cheaper: All Available Pathways

Cost is the central access barrier. The retail cash price for Jardiance 10 mg (30 tablets) runs approximately $620, $690 depending on the pharmacy. For Medicaid patients, copayments are federally capped at nominal amounts (currently $4.00 for preferred drugs, $8.00 for non-preferred drugs for most enrollees), so the actual out-of-pocket cost is low once coverage is approved. The harder problem is getting coverage approved in the first place.

Manufacturer Patient Assistance: Boehringer Ingelheim Cares Foundation

For patients who do not qualify for Medicaid or whose Medicaid application is pending, the Boehringer Ingelheim Cares Foundation provides free Jardiance to income-qualified patients. Eligibility generally requires household income at or below 400% of the federal poverty level and lack of adequate insurance coverage. Applications are submitted through the prescriber's office or via 1-800-556-8317. This program is the most direct route to zero-cost drug for uninsured or underinsured patients.

GoodRx, Mark Cuban Cost Plus Drugs, and Pharmacy Discount Cards

Empagliflozin has no FDA-approved generic as of early 2026, so discount card prices at retail pharmacies still reflect brand pricing. GoodRx coupons bring Jardiance to approximately $500, $560 at major chains, a modest reduction. Cost Plus Drugs does not currently carry Jardiance because Boehringer Ingelheim has not contracted with that platform. These programs cannot be combined with Medicaid.

Manufacturer Copay Card: Federal Program Exclusion

The Jardiance Savings Card (Boehringer Ingelheim/Lilly) reduces commercial-insurance cost-sharing to as low as $0/month for eligible patients. Federal law (anti-kickback statute and the AKS discount safe harbor) prohibits using manufacturer copay cards for prescriptions covered by any federal program, including Medicaid and Medicare Part D. A patient who uses a copay card while Medicaid is paying for the drug faces potential fraud liability. Medicaid patients should not use this card.

HSA and FSA Use

Jardiance is a prescription drug and qualifies as a medical expense under IRS Publication 502 (IRS Publication 502, 2024). Patients with a high-deductible health plan paired with a health savings account (HSA), or a flexible spending account (FSA) through their employer, can pay for Jardiance (or the related cost-sharing) with pre-tax dollars. This applies whether the prescription is filled under commercial insurance, during a deductible period, or as a cash-pay prescription. Medicaid beneficiaries generally do not have HSA accounts because Medicaid is not an HSA-compatible plan, but dual-eligible patients with commercial secondary coverage may have FSA access.

Navigating a Medicaid Prior Authorization for Jardiance

A PA denial is not a final answer. The process below applies to most state Medicaid programs and their MCO subcontractors.

Submitting the Initial PA Request

The prescriber's office submits a PA request form (paper or electronic via CoverMyMeds or similar platform) to the patient's Medicaid plan. The request should include: ICD-10 codes for the relevant indication (E11.xx for T2DM, I50.2x for HFrEF, N18.x for CKD), the most recent HbA1c or eGFR value, documentation of any prior SGLT2 agent trial, and the clinical rationale citing EMPA-REG OUTCOME or EMPA-KIDNEY where applicable.

First-Level Appeal

If the initial PA is denied, the prescriber has the right to file a first-level internal appeal with the plan. A letter should cite the ADA 2025 Standards of Care recommendation for SGLT2 inhibitors with proven benefit in high-cardiovascular-risk patients, the specific trial data, and the FDA label expansion. Most plans have a 72-hour expedited appeal timeline for clinically urgent situations.

External Appeal and State Fair Hearing

If the internal appeal is denied, the patient has the right to an external independent review and, separately, a state Medicaid fair hearing. Fair hearings are conducted by the state Medicaid agency and carry legal weight. The state must provide a decision within 90 days (or 3 days if expedited). The Centers for Medicare and Medicaid Services has published guidance on Medicaid managed care grievances and appeals at (42 CFR Part 438).

Empagliflozin Generic Timeline and Its Impact on Formulary Access

Generic empagliflozin is expected to reach the U.S. Market no earlier than 2025 to 2026 pending Boehringer Ingelheim's patent exclusivity. Once a generic is available, state Medicaid programs will almost certainly move generic empagliflozin to preferred status immediately, as they did with generic metformin and sulfonylureas. The FDA's Orange Book lists empagliflozin patent and exclusivity data (FDA Orange Book, empagliflozin). Prescribers and patients who face current access barriers may find the situation resolves with generic entry.

Dual Eligibles: Medicare-Medicaid Overlap

Patients eligible for both Medicare and Medicaid ("dual eligibles") receive their prescription drug benefit through Medicare Part D, not Medicaid, in most states. For these patients, Jardiance coverage depends on the Part D formulary of their enrolled plan, not the state Medicaid PDL. Low-Income Subsidy (LIS or "Extra Help") recipients pay $0, $11.20 per fill for covered drugs in 2026. If Jardiance is on the Part D plan's formulary at any tier, LIS covers most or all of the cost. If it is not covered, the Part D formulary exception process applies.